This study aimed to investigate the prognostic significance of TP53mut and PI3K/AKT pathway alterations in BC leveraging data from two of the largest, well-characterized BC cohorts: the Memorial Sloan Kettering (MSK) Cancer Center13 and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC).12,14 By integrating clinical and genomic data, we seek to elucidate how these genetic alterations influence survival outcomes and to identify potential interactions between TP53 and the PI3K/AKT pathway across distinct BC subtypes. The gene discussed is TP53; the disease is breast carcinoma.